Development of an optimized dual-targeted tandem VH-only fully-human CAR to generate long-term durable remission with adoptive cellular therapy for multiple myeloma

Description

This project aims to develop an optimized dual-targeted tandem VH-only fully-human CAR for the treatment of multiple myeloma, aiming to achieve durable remissions. Specific aims include analyzing factors associated with CAR T cell manufacturing success, predicting CAR T cell expansion post-infusion, correlating T cell composition with side effects, identifying markers for treatment response and resistance, and comparing T cell compartments from leukapheresis and autologous stem cell products. The project leverages previous advancements in CAR T cell therapy to enhance efficacy while minimizing toxicity, ultimately aiming to advance the therapy towards clinical translation.